Shareholder plans 11,446-share OCUL Rule 144 sale

Ocular Therapeutix shareholder Donald D Notman Jr. filed a notice of proposed sale under Rule 144 covering 11,446 shares of common stock.

Rhea-AI Filing Summary

Ocular Therapeutix shareholder Donald D Notman Jr. filed a notice of proposed sale under Rule 144 covering 11,446 shares of common stock. These shares came from restricted stock that vested under a registered plan on 02/11/2026 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

The filing notes that 217,691,779 common shares were outstanding. Over the prior three months, the same seller disposed of 6,035 shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88. The signer represents having no undisclosed material adverse information about Ocular Therapeutix.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OCUL Form 144 filing by Donald D Notman Jr. disclose?

The filing discloses a planned Rule 144 sale of 11,446 OCUL shares. These shares come from restricted stock that vested on 02/11/2026 and are intended to be sold on NASDAQ through Morgan Stanley Smith Barney LLC under Rule 144 resale provisions.

How many Ocular Therapeutix (OCUL) shares has the seller recently sold?

The seller reported two prior OCUL stock sales in the last three months. He sold 6,035 common shares on 02/04/2026 for gross proceeds of 51,540.71 and 5,455 shares on 02/02/2026 for 49,872.88, in addition to the newly planned 11,446-share sale.

What is the source of the 11,446 OCUL shares in the Form 144 filing?

The 11,446 OCUL shares come from restricted stock vesting. The filing states they were acquired on 02/11/2026 through restricted stock vesting under a registered plan from the issuer, with payment described as not applicable, indicating a non-cash equity award vesting.

Which broker will handle the planned OCUL share sale under Rule 144?

The planned OCUL sale will be handled by Morgan Stanley Smith Barney LLC. The broker’s Executive Financial Services office at 1 New York Plaza, 8th Floor, New York, NY 10004 is listed, and the shares are expected to be sold on the NASDAQ exchange.

How many Ocular Therapeutix (OCUL) shares were outstanding in the Form 144 disclosure?

The Form 144 lists 217,691,779 OCUL common shares outstanding. This figure provides context for the relative size of the planned 11,446-share Rule 144 sale and the two earlier sales, which together represent a very small portion of total shares.

What representation does the OCUL Form 144 seller make about company information?

The seller represents having no undisclosed material adverse information about OCUL. By signing the notice, the person states they do not know any material negative information about current or prospective operations that has not already been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:33 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001718019
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	15 Crosby Drive Bedford MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	DONALD D NOTMAN JR.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11446	103481.00	217691779	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/11/2026	Restricted stock vesting under a registered plan	Issuer			11446	02/11/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
DONALD D NOTMAN JR. 15 Crosby Drive Bedford MA 01730	Common	02/04/2026	6035	51540.71
DONALD D NOTMAN JR. 15 Crosby Drive Bedford MA 01730	Common	02/02/2026	5455	49872.88

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Donald D Notman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)